Search Results - "DEININGER, Michael W"

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors by Patel, Ami B., O’Hare, Thomas, Deininger, Michael W.

“…Chronic myeloid leukemia is increasingly viewed as a chronic illness; most patients have a life expectancy close to that of the general population. Despite…”
Get full text

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial by Cortes, Jorge E, Gambacorti-Passerini, Carlo, Deininger, Michael W, Mauro, Michael J, Chuah, Charles, Kim, Dong-Wook, Dyagil, Irina, Glushko, Nataliia, Milojkovic, Dragana, le Coutre, Philipp, Garcia-Gutierrez, Valentin, Reilly, Laurence, Jeynes-Ellis, Allison, Leip, Eric, Bardy-Bouxin, Nathalie, Hochhaus, Andreas, Brümmendorf, Tim H

“…Purpose Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) resistant…”
Get full text

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia by Hochhaus, Andreas, Larson, Richard A, Guilhot, François, Radich, Jerald P, Branford, Susan, Hughes, Timothy P, Baccarani, Michele, Deininger, Michael W, Cervantes, Francisco, Fujihara, Satoko, Ortmann, Christine-Elke, Menssen, Hans D, Kantarjian, Hagop, O’Brien, Stephen G, Druker, Brian J

“…After nearly 11 years of follow-up, long-term administration of imatinib was shown to be associated with prolonged control of chronic myeloid leukemia and no…”
Get full text

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial by Cortes, Jorge E., Kim, Dong-Wook, Pinilla-Ibarz, Javier, le Coutre, Philipp D., Paquette, Ronald, Chuah, Charles, Nicolini, Franck E., Apperley, Jane F., Khoury, H. Jean, Talpaz, Moshe, DeAngelo, Daniel J., Abruzzese, Elisabetta, Rea, Delphine, Baccarani, Michele, Müller, Martin C., Gambacorti-Passerini, Carlo, Lustgarten, Stephanie, Rivera, Victor M., Haluska, Frank G., Guilhot, François, Deininger, Michael W., Hochhaus, Andreas, Hughes, Timothy P., Shah, Neil P., Kantarjian, Hagop M.

“…Ponatinib has potent activity against native and mutant BCR-ABL1, including BCR-ABL1T315I. The pivotal phase 2 Ponatinib Ph+ ALL and CML Evaluation (PACE)…”
Get full text

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias by Cortes, Jorge E, Kantarjian, Hagop, Shah, Neil P, Bixby, Dale, Mauro, Michael J, Flinn, Ian, O'Hare, Thomas, Hu, Simin, Narasimhan, Narayana I, Rivera, Victor M, Clackson, Tim, Turner, Christopher D, Haluska, Frank G, Druker, Brian J, Deininger, Michael W.N, Talpaz, Moshe

“…Ponatinib was developed to overcome resistance to the tyrosine kinase inhibitors used to treat leukemias that are positive for the Philadelphia chromosome. In…”
Get full text

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia by O'Hare, Thomas, Eide, Christopher A., Deininger, Michael W.N.

“…Mutations in the kinase domain (KD) of BCR-ABL are the most prevalent mechanism of acquired imatinib resistance in patients with chronic myeloid leukemia…”
Get full text

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 by Baccarani, Michele, Deininger, Michael W., Rosti, Gianantonio, Hochhaus, Andreas, Soverini, Simona, Apperley, Jane F., Cervantes, Francisco, Clark, Richard E., Cortes, Jorge E., Guilhot, François, Hjorth-Hansen, Henrik, Hughes, Timothy P., Kantarjian, Hagop M., Kim, Dong-Wook, Larson, Richard A., Lipton, Jeffrey H., Mahon, François-Xavier, Martinelli, Giovanni, Mayer, Jiri, Müller, Martin C., Niederwieser, Dietger, Pane, Fabrizio, Radich, Jerald P., Rousselot, Philippe, Saglio, Giuseppe, Saußele, Susanne, Schiffer, Charles, Silver, Richard, Simonsson, Bengt, Steegmann, Juan-Luis, Goldman, John M., Hehlmann, Rüdiger

“…Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A…”
Get full text

Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML by Maxson, Julia E, Gotlib, Jason, Pollyea, Daniel A, Fleischman, Angela G, Agarwal, Anupriya, Eide, Christopher A, Bottomly, Daniel, Wilmot, Beth, McWeeney, Shannon K, Tognon, Cristina E, Pond, J. Blake, Collins, Robert H, Goueli, Basem, Oh, Stephen T, Deininger, Michael W, Chang, Bill H, Loriaux, Marc M, Druker, Brian J, Tyner, Jeffrey W

“…Nearly 60% of patients with chronic neutrophilic leukemia (CNL) or atypical chronic myeloid leukemia (i.e., lacking the BCR-ABL1 translocation) have mutations…”
Get full text

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial by Brümmendorf, Tim H., Cortes, Jorge E., Milojkovic, Dragana, Gambacorti-Passerini, Carlo, Clark, Richard E., le Coutre, Philipp, Garcia-Gutierrez, Valentin, Chuah, Charles, Kota, Vamsi, Lipton, Jeffrey H., Rousselot, Philippe, Mauro, Michael J., Hochhaus, Andreas, Hurtado Monroy, Rafael, Leip, Eric, Purcell, Simon, Yver, Anne, Viqueira, Andrea, Deininger, Michael W.

“…This analysis from the multicenter, open-label, phase 3 BFORE trial reports efficacy and safety of bosutinib in patients with newly diagnosed chronic phase…”
Get full text

Turning the tide in myelodysplastic/myeloproliferative neoplasms by Deininger, Michael W. N., Tyner, Jeffrey W., Solary, Eric

“…Key Points Myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) are aggressive haematopoietic malignancies that combine myeloid cell dysplasia and…”
Get full text

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial by Verstovsek, Srdan, Mesa, Ruben A, Gotlib, Jason, Gupta, Vikas, DiPersio, John F, Catalano, John V, Deininger, Michael W N, Miller, Carole B, Silver, Richard T, Talpaz, Moshe, Winton, Elliott F, Harvey, Jr, Jimmie H, Arcasoy, Murat O, Hexner, Elizabeth O, Lyons, Roger M, Paquette, Ronald, Raza, Azra, Jones, Mark, Kornacki, Deanna, Sun, Kang, Kantarjian, Hagop

“…The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with…”
Get full text

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia by Carey, Alyssa, Edwards, David K., Eide, Christopher A., Newell, Laura, Traer, Elie, Medeiros, Bruno C., Pollyea, Daniel A., Deininger, Michael W., Collins, Robert H., Tyner, Jeffrey W., Druker, Brian J., Bagby, Grover C., McWeeney, Shannon K., Agarwal, Anupriya

“…Secreted proteins in the bone marrow microenvironment play critical roles in acute myeloid leukemia (AML). Through an ex vivo functional screen of 94…”
Get full text

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial by Lipton, Jeffrey H, Prof, Chuah, Charles, MD, Guerci-Bresler, Agnès, MD, Rosti, Gianantonio, Prof, Simpson, David, Prof, Assouline, Sarit, MD, Etienne, Gabriel, MD, Nicolini, Franck E, MD, le Coutre, Philipp, Prof, Clark, Richard E, Prof, Stenke, Leif, MD, Andorsky, David, MD, Oehler, Vivian, MD, Lustgarten, Stephanie, PhD, Rivera, Victor M, PhD, Clackson, Timothy, PhD, Haluska, Frank G, MD, Baccarani, Michele, Prof, Cortes, Jorge E, Prof, Guilhot, François, Prof, Hochhaus, Andreas, Prof, Hughes, Timothy, Prof, Kantarjian, Hagop M, Prof, Shah, Neil P, Prof, Talpaz, Moshe, Prof, Deininger, Michael W, Prof

“…Summary Background Ponatinib has shown potent activity against chronic myeloid leukaemia that is resistant to available treatment, although it is associated…”
Get full text

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors by Davare, Monika A., Vellore, Nadeem A., Wagner, Jacob P., Eide, Christopher A., Goodman, James R., Drilon, Alexander, Deininger, Michael W., O’Hare, Thomas, Druker, Brian J.

“…Oncogenic ROS1 fusion proteins are molecular drivers in multiple malignancies, including a subset of non-small cell lung cancer (NSCLC). The phylogenetic…”
Get full text

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia by Zabriskie, Matthew S., Eide, Christopher A., Tantravahi, Srinivas K., Vellore, Nadeem A., Estrada, Johanna, Nicolini, Franck E., Khoury, Hanna J., Larson, Richard A., Konopleva, Marina, Cortes, Jorge E., Kantarjian, Hagop, Jabbour, Elias J., Kornblau, Steven M., Lipton, Jeffrey H., Rea, Delphine, Stenke, Leif, Barbany, Gisela, Lange, Thoralf, Hernández-Boluda, Juan-Carlos, Ossenkoppele, Gert J., Press, Richard D., Chuah, Charles, Goldberg, Stuart L., Wetzler, Meir, Mahon, Francois-Xavier, Etienne, Gabriel, Baccarani, Michele, Soverini, Simona, Rosti, Gianantonio, Rousselot, Philippe, Friedman, Ran, Deininger, Marie, Reynolds, Kimberly R., Heaton, William L., Eiring, Anna M., Pomicter, Anthony D., Khorashad, Jamshid S., Kelley, Todd W., Baron, Riccardo, Druker, Brian J., Deininger, Michael W., O’Hare, Thomas

“…Ponatinib is the only currently approved tyrosine kinase inhibitor (TKI) that suppresses all BCR-ABL1 single mutants in Philadelphia chromosome-positive (Ph+)…”
Get full text

Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia by O'HARE, Thomas, DEININGER, Michael W. N, EIDE, Christopher A, CLACKSON, Tim, DRUKER, Brian J

“…Beginning with imatinib a decade ago, therapy based on targeted inhibition of the BCR-ABL kinase has greatly improved the prognosis for chronic myeloid…”
Get full text

Chronic myeloid leukemia: reminiscences and dreams by Mughal, Tariq I, Radich, Jerald P, Deininger, Michael W, Apperley, Jane F, Hughes, Timothy P, Harrison, Christine J, Gambacorti-Passerini, Carlo, Saglio, Giuseppe, Cortes, Jorge, Daley, George Q

“…With the deaths of Janet Rowley and John Goldman in December 2013, the world lost two pioneers in the field of chronic myeloid leukemia. In 1973, Janet Rowley,…”
Get full text

BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships by Khorashad, Jamshid S., Kelley, Todd W., Szankasi, Philippe, Mason, Clinton C., Soverini, Simona, Adrian, Lauren T., Eide, Christopher A., Zabriskie, Matthew S., Lange, Thoralf, Estrada, Johanna C., Pomicter, Anthony D., Eiring, Anna M., Kraft, Ira L., Anderson, David J., Gu, Zhimin, Alikian, Mary, Reid, Alistair G., Foroni, Letizia, Marin, David, Druker, Brian J., O'Hare, Thomas, Deininger, Michael W.

“…BCR-ABL1 compound mutations can confer high-level resistance to imatinib and other ABL1 tyrosine kinase inhibitors (TKIs). The third-generation ABL1 TKI…”
Get full text

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms by Tyner, Jeffrey W., Bumm, Thomas G., Deininger, Jutta, Wood, Lisa, Aichberger, Karl J., Loriaux, Marc M., Druker, Brian J., Burns, Christopher J., Fantino, Emmanuelle, Deininger, Michael W.

“…Activating alleles of Janus kinase 2 (JAK2) such as JAK2V617F are central to the pathogenesis of myeloproliferative neoplasms (MPN), suggesting that small…”
Get full text

Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial by MESA, Ruben A, GOTLIB, Jason, HARVEY, Jimmie H, HARE, Thomas, ERICKSON-VIITANEN, Susan, SUN, William, SANDOR, Victor, LEVY, Richard S, KANTARJIAN, Hagop M, VERSTOVSEK, Srdan, GUPTA, Vikas, CATALANO, John V, DEININGER, Michael W, SHIELDS, Alan L, MILLER, Carole B, SILVER, Richard T, TALPAZ, Moshe, WINTON, Elliott F

“…To assess the effects of ruxolitinib on symptom burden and quality of life (QoL) and to evaluate the ability of the modified Myelofibrosis Symptom Assessment…”
Get full text